What is the Share Price of Wanbury Ltd?
- Answer Field
-
The share price of Wanbury Ltd for NSE is ₹ 312.20 and for BSE is ₹ 316.00.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, Wanbury share price is currently at ₹ 312.2, which is up by ₹ 0.00 from its previous closing. Today, the stock has fluctuated between ₹ 303.00 and ₹ 320.95. Over the past year, Wanbury has achieved a return of 98.37 %. In the last month alone, the return has been 16.30 %. Read More...
Particulars | MAR 2025 (Values in Cr) |
---|---|
Revenue | 172.00 |
Operating Expense | 154.79 |
Net Profit | 20.26 |
Net Profit Margin (%) | 11.77 |
Earnings Per Share (EPS) | 6.18 |
EBITDA | 31.46 |
Effective Tax Rate (%) | -6.29 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.36 | 27.76 | 1.99 | 278.64 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 149.35 | 18.67 | 1.49 | 1573.70 | 101.00 / 184.95 |
CIPLA LTD | 1505.40 | 23.06 | 3.89 | 121589.70 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 338.10 | 12.94 | 2.74 | 995.06 | 163.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.36 | 36.36 | 5.74 | 278.64 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 697.60 | 39.68 | 6.17 | 2016.81 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 10524.65 | 150.31 | 34.15 | 26311.63 | 6160.25 / 10653.05 |
BLISS GVS PHARMA LTD | 149.35 | 22.80 | 1.48 | 1573.70 | 101.00 / 184.95 |
The Wanbury share price has experienced fluctuations following the company’s recent financial results. Wanbury reported moderate revenue growth, driven by strong demand in the pharmaceutical sector. However, profit margins were impacted by rising input costs and operational expenses. The company’s focus on expanding its product portfolio and enhancing its manufacturing capabilities contributed positively to overall revenue. Despite these efforts, net profit remained under pressure, reflecting the challenges faced in maintaining profitability. Nevertheless, Wanbury’s strategic initiatives in research and development have positioned it for future growth, keeping the Wanbury share price stable, with cautious optimism from investors about the company’s long-term performance.
Wanbury’s annual reports provide a comprehensive overview of the company’s financial performance, which directly impacts the Wanbury share price. The reports highlight key metrics such as revenue growth, operational efficiency, and cost management. They also outline the company’s strategic initiatives, including investments in research and development, which are essential for future growth. Investors use these reports to assess Wanbury’s financial stability and long-term potential. The annual reports are crucial for understanding the company’s progress and the factors that drive the Wanbury share price, offering valuable insights into its operational and financial outlook.
Wanbury has not been a regular dividend-paying company in recent years due to its focus on reinvesting profits into business expansion and research initiatives. The company’s primary goal has been to strengthen its financial position and improve operational efficiencies. As a result, dividend payments have been limited, which may not attract income-focused investors. However, as Wanbury continues to stabilise its financial performance, future dividend payouts may become a possibility. This strategic reinvestment has helped support the long-term stability of the Wanbury share price.
Wanbury Ltd (Formerly known Pearl Organics Limited) was incorporated in August, 1988. The Company is engaged in the business of pharmaceutical and related activities, including research.
The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs. In 1995, the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga. In 1996, it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US.
In 2007-08, the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April, 2007. Pursuant to the aforesaid Order of the Hon'ble Bl FR 7,85,557 Equity Shares of face value of Rs. 10/- each of the Company were issued to the Equity Shareholders of DOCL on 17th March, 2008. Similarly, the Pharmaceutical Products of India Limited (PPIL) was merged with the Company effective from April 1, 2006. In terms of the said Scheme of Merger, the Company had issued 5,62,618 Equity Shares of face value of Rs. 10/- each to the Equity Shareholders of PPIL on 27 June, 2007, which got listed on Bombay Stock Exchange Limited and National Stock Exchange Limited respectively.
The company entered into a strategic association with Bravo Healthcare Ltd and incorporated Ningxia Wanbury Fine Chemicals Co Ltd to source raw materials from China. It opened its office in Zurich,Switzerland for its CRAMS business and incorporated Wanbury Global FZE in Middle East for carrying out its trading activities in the year 2008.
The novel product 'Cdense Gems' was launched in May, 2008. The Company completed the restructuring of the Formulation Division during the year 2013. It launched, Myotol-F, targeted at female infertility in 2013, it launched Folinine. The Company's newly launched products Myotol-F (to treat polycystic ovarian syndrome) and Cal-K2 (in prevention and management of Osteoporosis) were labelled as one of the best launches in 2014.
The share price of Wanbury Ltd for NSE is ₹ 312.20 and for BSE is ₹ 316.00.
The market cap of Wanbury Ltd for NSE is ₹ 1,022.31 Cr. and for BSE is ₹ 1,034.75 Cr. as of now.
The 52 Week High and Low of Wanbury Ltd for NSE is ₹ 329.70 and ₹ 152.81 and for BSE is ₹ 330.00 and ₹ 151.10.
You can trade in Wanbury Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 98.37%.
Wanbury Ltd share price is for NSE ₹ 312.20 & for BSE ₹ 316.00 as on Jun 16 2025 01:22 PM.
The market cap of Wanbury Ltd for NSE ₹ 1,022.31 & for BSE ₹ 1,034.75 as on Jun 16 2025 01:22 PM.
As on Jun 16 2025 01:22 PM the price-to-earnings (PE) ratio for Wanbury Ltd share is 33.71.
As on Jun 16 2025 01:22 PM, the price-to-book (PB) ratio for Wanbury Ltd share is 18.08.
You can trade in Wanbury Ltd shares with Bajaj Broking by opening a demat account.
To buy Wanbury Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Wanbury Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found